Novaminsulfon (Metamizole Sodium)

Metamizole sodium, the active ingredient in Novaminsulfon, is a non‑opioid analgesic (pyrazolone derivative) presented as an oral formulation for oral use. It is employed to relieve moderate to severe pain and to reduce fever in adult patients when other treatments are insufficient or not tolerated.

GNH USA supplies Novaminsulfon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novaminsulfon is a non‑opioid analgesic used in several clinical situations where pain or fever control is required.

- Pain: provides relief of moderate to severe acute or chronic pain. - Fever: reduces elevated body temperature associated with infection or inflammation. - Postoperative pain: helps manage pain following surgical procedures. - Colic: alleviates visceral pain such as renal or biliary colic.

Novaminsulfon may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes after dosing. - Dizziness: transient light‑headedness. - Rash: mild skin erythema. - Elevated liver enzymes: transient laboratory changes.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, requiring immediate medical attention. - Anaphylactic reactions: rare but potentially life‑threatening hypersensitivity. - Severe hypotension: abrupt drop in blood pressure. - Hepatotoxicity: rare liver injury. - Hemolysis: uncommon breakdown of red blood cells.

Before prescribing Novaminsulfon, clinicians should consider patient‑specific factors and monitor for potential complications.

- Renal impairment: adjust use and monitor kidney function. - Hepatic disease: use with caution and assess liver enzymes. - History of blood dyscrasias: avoid in patients with prior agranulocytosis. - Concomitant immunosuppressants: monitor for additive bone‑marrow suppression. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Novaminsulfon can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other myelosuppressive agents: heightened risk of agranulocytosis.

Moderate Interactions (Monitor Closely): - NSAIDs: additive gastrointestinal irritation. - ACE inhibitors or diuretics: possible reduction in antihypertensive effect. - Lithium: potential for increased lithium levels. - Methotrexate: may enhance toxicity. - CYP450 substrates: possible alteration of metabolism.